Overview
- JPMorgan lifted Recursion to Overweight from Neutral and increased its price target to $11 from $10.
- Analyst Eric Joseph labeled REC‑4881 a potential blockbuster, projecting peak U.S. sales above $1 billion with a 60% chance of success.
- REC‑617 showed promising early results in platinum‑resistant ovarian cancer, which the firm emphasized are preliminary.
- Recursion shares traded up about 18% intraday to roughly $4.95 on Wednesday, according to Benzinga Pro.
- Attention to the name also reflected reports that major AI firms are exploring biotech data partnerships, and Recursion’s Nvidia backing was noted, though the company was not named in the report.